News & Events
ST. LOUIS, MO – Aug. 20, 2013– Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announcedthat it has signed a research agreement with The Hamner Institutes for Health Sciences. Under this research agreement, Certara and The Hamner will explore the scientific benefits of using Certara’s Simcyp™ Simulator to drive hepatic drug exposure within The Hamner’s population-based, drug-induced liver injury (DILI) model. The partners plan to integrate The Hamner’s DILIsym® modeling software into Certara’s Simcyp Population-based Simulator and test the integrated product’s simulation capabilities with respect to drug exposure and resultant liver toxicity. Both of these systems are used by several leading international pharmaceutical companies.
RESEARCH TRIANGLE PARK, NC – The Hamner Institutes for Health Sciences (www.thehamner.org) announces the release of DILIsym® v2B and MITOsym™ v1A. DILIsym® and MITOsym™ software are developed and released as part of the DILI-sim Initiative (www.dilisym.com), an effort to develop a mathematical, mechanistic model of drug-induced liver injury chaired by Dr. Paul B. Watkins. DILIsym® v2B and MITOsym™ v1A were made available to all DILI-sim Initiative industry members as of July 24th, 2013.
MEDFORD, Mass. & RESEARCH TRIANGLE PARK, N.C.-- August 6, 2013 -- Hepregen Corporation, developer of next generation HepatoPacTM and HepatoMuneTM products, and The Hamner Institutes for Health Sciences, a nonprofit research organization focused on translational safety sciences, announced today execution of an agreement that provides for a research partnership between the two entities. The research effort will be led by Dr. Edward LeCluyse, Associate Investigator at The Hamner, and Dr. Michael Holsapple, newly appointed Vice President of Toxicology Product Development at Hepregen, along with Mr. Jack McGeehan, Hepregen’s Vice President of Operations. The partnership will focus on research and development efforts aimed at defining: (1) basic concepts regarding the potential for new micro-liver products and (2) new applications and assay methodologies for Hepregen’s existing micro-liver products that are already transforming pharmaceutical product development.